Media headlines about Oncomed Pharmaceuticals (NASDAQ:OMED) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Oncomed Pharmaceuticals earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 47.383782344609 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
A number of brokerages have weighed in on OMED. Jefferies Group restated a “buy” rating and issued a $5.00 price objective on shares of Oncomed Pharmaceuticals in a report on Thursday, September 28th. Zacks Investment Research upgraded Oncomed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.75 target price for the company in a research note on Wednesday, October 4th. Cantor Fitzgerald reissued a “hold” rating and issued a $6.00 target price on shares of Oncomed Pharmaceuticals in a report on Tuesday, September 19th. Finally, SunTrust Banks reaffirmed a “hold” rating and set a $4.00 price objective on shares of Oncomed Pharmaceuticals in a report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $5.94.
Shares of Oncomed Pharmaceuticals (OMED) traded down $0.32 on Tuesday, reaching $4.58. The company had a trading volume of 126,900 shares, compared to its average volume of 279,366. Oncomed Pharmaceuticals has a 1 year low of $2.91 and a 1 year high of $10.89.
Oncomed Pharmaceuticals (NASDAQ:OMED) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.13. The business had revenue of $5.11 million for the quarter, compared to the consensus estimate of $6.25 million. During the same quarter in the previous year, the firm posted ($0.77) EPS. The business’s revenue was down 13.7% on a year-over-year basis. equities analysts anticipate that Oncomed Pharmaceuticals will post -1.62 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Oncomed Pharmaceuticals (OMED) Receives Daily Coverage Optimism Score of 0.19” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/05/oncomed-pharmaceuticals-omed-earning-somewhat-favorable-news-coverage-analysis-finds.html.
Oncomed Pharmaceuticals Company Profile
OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).
Receive News & Ratings for Oncomed Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.